---
title: "BioKangtai released its performance for the first half of the year, with a net profit attributable to the parent company of 37.5327 million yuan, a decrease of 77.30%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253996731.md"
description: "BioKangtai released its 2025 semi-annual report, with operating revenue of 1.392 billion yuan, a year-on-year increase of 15.81%. The net profit attributable to the parent company was 37.5327 million yuan, a year-on-year decrease of 77.30%; the net profit after deducting non-recurring gains and losses was 18.4586 million yuan, a year-on-year decrease of 84.85%. The basic earnings per share were 0.03 yuan"
datetime: "2025-08-21T12:31:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253996731.md)
  - [en](https://longbridge.com/en/news/253996731.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253996731.md)
generator: "portal-rs"
---

# BioKangtai released its performance for the first half of the year, with a net profit attributable to the parent company of 37.5327 million yuan, a decrease of 77.30%

According to the Zhitong Finance APP, BioKangtai (300601.SZ) released its semi-annual report for 2025, showing an operating income of 1.392 billion yuan, a year-on-year increase of 15.81%. The net profit attributable to shareholders of the listed company was 37.5327 million yuan, a year-on-year decrease of 77.30%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 18.4586 million yuan, a year-on-year decrease of 84.85%. The basic earnings per share were 0.03 yuan

### Related Stocks

- [300601.CN](https://longbridge.com/en/quote/300601.CN.md)

## Related News & Research

- [SuperH™ 5K Run, Walk & Wheel Supports Adaptive Sports Athletes at MedStar National Rehabilitation Hospital](https://longbridge.com/en/news/298958824.md)
- [Sepsis Diagnostics Market worth $1.22 billion by 2031 - Exclusive Report by MarketsandMarkets™](https://longbridge.com/en/news/298745982.md)
- [Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer](https://longbridge.com/en/news/298831859.md)
- [Precise Biometrics Extends IOTRUST Partnership for Next-Gen DCENT Crypto Wallets](https://longbridge.com/en/news/299006377.md)
- [ABEC to expand global manufacturing network with new Wilson facility](https://longbridge.com/en/news/298710451.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**